Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Modified-Release Drug Delivery Systems: Drug Release Characteristics01:22

Modified-Release Drug Delivery Systems: Drug Release Characteristics

Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Influencing Factors01:20

Modified-Release Drug Delivery Systems: Influencing Factors

Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design and characterization of a resveratrol spray-dried inhalable formulation for pulmonary delivery with <i>in vivo</i> pharmacokinetic and toxicological evaluation.

Drug delivery·2026
Same author

In vitro comparison of aerosol deposition by albuterol pMDI using corrugated tubing versus a commercial spacer.

International journal of pharmaceutics·2026
Same author

Multi-mechanistic mitochondria-mediated N-methylated YKWYYRGAA-decorated nano-chitosan conjugate carrier for treatment of NRAS-mutant-harbouring lung carcinoma.

Carbohydrate polymers·2026
Same author

Repurposing insulin for Alzheimer's disease treatment: intranasal delivery of a thermoresponsive nanocarrier-based insulin formulation to the brain.

Drug delivery and translational research·2026
Same author

Soft‑mist inhaler spray dynamics and laryngeal deposition in upper airway models.

Expert opinion on drug delivery·2026
Same author

The Advanced Integrated Respiratory (AIR) Model: Integration of Air-Liquid Interface Cell Cultures within a Human Airway Model for Inhalation Toxicology.

Pharmaceutical research·2026

Related Experiment Video

Updated: Jun 22, 2026

Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models
07:56

Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models

Published on: November 11, 2020

Recent advances in controlled release pulmonary therapy.

Rania Salama1, Daniela Traini, Hak-Kim Chan

  • 1Advanced Drug Delivery Group, Faculty of Pharmacy, University of Sydney, Sydney NSW 2006, Australia.

Current Drug Delivery
|June 19, 2009
PubMed
Summary

Controlled release inhalation formulations are crucial for respiratory illnesses but face challenges like particle size and lung physiology. This review details advances, challenges, and essential evaluation methodologies for these advanced drug delivery systems.

More Related Videos

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
05:45

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis

Published on: January 16, 2026

Related Experiment Videos

Last Updated: Jun 22, 2026

Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models
07:56

Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models

Published on: November 11, 2020

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
05:45

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis

Published on: January 16, 2026

Area of Science:

  • Pharmaceutical Sciences
  • Drug Delivery
  • Respiratory Medicine

Background:

  • Targeted delivery to airways maximizes lung concentration and minimizes systemic exposure.
  • No controlled release inhalation formulations are currently available for respiratory illnesses.
  • Particle engineering is key for effective inhalation therapies.

Purpose of the Study:

  • To review current advances in controlled release inhalation formulations.
  • To discuss particle engineering strategies and characterization methodologies.
  • To highlight challenges and necessary evaluation techniques for these formulations.

Main Methods:

  • Review of existing literature on controlled release inhalation formulations.
  • Discussion of particle engineering strategies (e.g., liposomal systems, microparticles, matrices).
  • Exploration of in vitro and in vivo evaluation methodologies for characterization.

Main Results:

  • Challenges include achieving controlled release with small particle sizes and considering lung physiology.
  • Toxicological and inflammatory effects of release-modifying agents require thorough investigation.
  • Various strategies exist, including molecular dispersions, lipid-based systems, and biodegradable matrices.

Conclusions:

  • Standardized pharmacopoeial methodologies for in vitro and in vivo testing are lacking.
  • Development requires addressing particle size effects, lung physiology, and excipient safety.
  • Further research into standardized evaluation is essential for market approval of controlled release inhalation therapies.